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ABSTRACT 
Nanomedicine is the use of nanoscale or nanostructured materials in medicine that due 
to their structure have unique medical effects. Prominent applications of nanomedicine 
are the use of nanomaterials for the delivery of drugs and nucleic acids (to correct gene 
defects). Nanomaterials offer several attractive features as delivery vehicles: First, their 
size in the nano-regime endows them with more desirable pharmacokinetic and 
biodistribution profiles in vivo. Second, they are amenable to diverse chemical 
engineering that enables loading of a wide range of substances. Third, they can protect 
therapeutic agents from premature degradation or from inducing undesired side effects. 
 
In this thesis, two types of synthetic nanomaterials, namely silica and polythiophene, 
were investigated for their biocompatibility and applications in gene delivery. 
 
In Paper I, human red blood cell hemolysis and premyelocytic leukemia HL-60 cell 
cytotoxicity induced by silica nanoparticles with distinct physicochemical properties 
were studied, suggesting that silica nanoparticles potentially induce membrane 
permeability through a universal mechanism of action. Moreover, plasma protected 
against silica nanoparticle-induced membrane damage primarily by shielding the 
surface of silica particles.  
 
In Paper II, the cytotoxicity and oxidative stress induced by amorphous silica 
nanoparticles were compared to nanoparticles with similar size but different chemical 
compositions. Overexpression of the liver phase II enzyme microsomal glutathione 
transferase 1 (MGST1) in human breast carcinoma MCF-7 cells reversed the 
cytotoxicity and oxidative stress induced by some silica nanoparticles but did not 
protect against the cytotoxic effects induced by zinc oxide nanoparticles.  
 
In Paper III, amino-functionalized silica nanoparticles were used to deliver plasmid 
DNA (pDNA) into human breast carcinoma MCF-7 cells, with the nonporous particles 
delivering pDNA at higher efficiency than their mesoporous counterparts (with 2.4 nm 
pore diameter).  
 
In Paper IV, polythiophene nanoparticles were used as vectors to deliver small 
interference RNA (siRNA) into human osteosarcoma U2-OS cells and human cervical 
carcinoma HeLa cells. The cationic polythiophenes were considerably more efficient 
delivery vectors than their zwitteronic counterparts.  
 
In conclusion, studies to improve the understanding of the biocompatibility and 
delivery efficiency of nanomaterials, are crucial to assist the rationale design of 
nanomaterials for delivery applications. 
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1 NANOMEDICINE: A BRIEF INTRODUCTION 
 
‘Nano-’ is a prefix derived from the Greek ‘!"!#$’ signifying ‘dwarf’, and refers to a 
billionth (10
-9
) in the metric system. Nanomedicine is the use of nanoscale or 
nanostructured materials in medicine that, due to their size or structure, have unique 
medical effects 
1
. The field of nanomedicine is therefore highly multidisciplinary in 
nature, integrating knowledge from nanosciences to medical sciences 
2
.  
 
One of the most prominent applications of nanomaterials in biomedicine is their use for 
delivery of pharmaceutical agents such as drugs and nucleic acids into the human body. 
In the year 2003 alone, drug delivery systems accounted for 59% of more than 2,000 
patent filings in the arena of nanomedicine 
1
. In april 2006, Nature Materials estimated 
that 130 nanotechnology based delivery systems were being developed worldwide 
3
. 
Some examples of nanomaterial-based delivery that already exist on the market are 
shown in Table 1. Nanomaterials offer several advantages as delivery vectors. First, 
their small size per se allows them to escape the recognition and clearance by the 
reticuloendothelial system (RES) and to cross biological barriers. This endows them 
with the capability to alter the pharmacokinetic and biodistribution profiles of 
therapeutic agents in vivo 
4
. A certain size range of nanomaterials is also particularly 
useful since it allows passive accumulation of nanomaterials in tumors by exploiting 
the characteristic large vasculature and defective lymphatic drainage of tumor tissues, 
an effect termed enhanced permeation and retention (EPR) 
5
. Second, their chemical 
versatility makes them suitable for loading a wide range of substances enabling 
multifunctionality 
6
 (Figure 1). For instance, nanomaterials can be engineered for both 
diagnostic and therapeutic purposes, holding great promises for personalized medicine 
7
. Moreover, appropriate designs can be made to achieve specific functionalities such as 
active targeting of cells as well as controlled release of therapeutic cargo upon the 
stimuli of choice (e.g. thermal, pH, enzymatic, photochemical triggered processes), in 
order to protect therapeutic agents from undesired interactions with the body and 
maximize their bioavailability at specific target sites over a period of time 
8
. In 
summary, the primary driving forces for nanomaterial-based delivery to meet medical 
needs are: (a) the ability to improve pharmacokinetic and biodistribution profiles, (b) 
the amenability to diverse chemical engineering, and (c) the protection of therapeutic 
agents from undesired reactions. 
 
Table 1. Examples of nanomaterial therapeutics on the market (nanomaterials used for 
the delivery of pharmaceutical agents) 
1
. 
 
Therapeutic 
Agent  
Nanomaterial 
Formulation 
Company Indication 
Ambisome Liposomal 
Amphotericin B 
Gilead, Fujisawa Fungal infections 
Doxil/Caelyx Liposomal Ortho Biotech, Cancer, Kaposi 
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doxorubicin Schering-Plough sarcoma 
Visudyne Liposomal 
verteporfin 
QLT, Novartis Age-related 
macular 
degeneration 
Copaxone Copolymer of 
alanine, lysine, 
glutamic acid and 
tyrosine 
TEVA 
Pharmaceuticals 
Multiple sclerosis 
Renagel Crosslinked 
poly(allylamine) 
resin 
Genzyme Chronic kidney 
disease 
Emend Nanocrystalline 
aprepitant 
Elan Drug 
Delivery 
Antiemetic 
Rapamune Nanocrystalline 
sirolimus 
Elan Drug 
Delivery 
Immuno-
suppressant 
Triglide Nanocrystalline 
fenofibrate 
SkyePharma Lipid regulation 
Abraxane Paclitaxel protein 
bound 
nanoparticles 
Abraxis 
BioSciences, 
AstraZeneca 
Cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Multifunctional nanoparticles 
6
. 
 
Moreover, a wide range of other biomedical applications of nanomaterials include in 
vivo imaging and diagnostics, regenerative medicine, infection biology, 
neuroelectronics, biosensors and so on 
1, 9-11
. Many of which make use of properties of 
materials that differ on the nanoscale (as compared to bulk materials of the same 
composition) owing to surface chemistry and/or quantum effects, giving rise to novel 
optical, electric, and magnetic properties 
1
.  
 
This thesis focuses on the biomedical applications of nanomaterials for gene delivery.  
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2 NANOMATERIALS AND THEIR PHYSICOCHEMICAL 
PROPERTIES 
 
An introduction to the world of nanosciences started with Richard Feynman’s classic 
talk in 1959 "There’s plenty of room at the bottom – an invitation to enter a new field 
of physics" 
12
. Nanomaterials are generally defined as materials in size ranging from 1 
to 100 nm at least in one dimension, although it has been pointed out that novel size-
dependent properties rather than arbitrary size thresholds is a more appropriate 
definition in some contexts 
13
. Therefore the broad definition of nanomaterials 
encompasses materials from a few nanometers to several micrometers in size. 
Nanoparticles have all three dimensions in this scale, whereas nanotubes have two 
dimensions and nanosurfaces have one dimension in this scale. Importantly, 
nanomaterials can be in the same size range as elements of living cells, including 
subcellular organelles and biomacromolecules (proteins, lipids, nucleic acids) (Table 
2).  
 
Table 2. Nanomaterials are in the same size range as elements of living cells. 
 
 
 
A water molecule is around 0.1 nm in width and length. 
 
 
A glucose molecule has a diameter around 1 nm.  
 The DNA double helix has a width around 2 nm and one 
nucleotide unit measures 0.33 nm long 
14
. 
 
 
 
An antibody is around 10-20 nm in diameter 
15
. 
 
 
 
 
Cellular structure and intracellular organelles: the 
thickness of cell membranes is around 7 nm 
16
, and the 
diameter of the nuclear pore is around 50 nm 
17
; the 
nucleus is around 3-10 µm, the mitochondrion 3 µm, and 
the endosome 200-500 nm in diameter. 
 
 
 
Cells: A typical human red blood cell has a disk diameter 
of 7-8 µm, a human macrophage is about 20 µm in 
diameter, and a human egg about 100 µm in diameter. 
 
Synthetic nanomaterials include several important classes of nanomaterials, such as 
carbon nanotubes, metal nanoparticles, oxide nanoparticles, quantum dots, polymers 
and liposomes 
18
. They can be further engineered to derive a large pool of derivatives. 
Synthetic nanomaterials have wide applications in nanotechnology and nanomedicine. 
This thesis focuses on two categories of synthetic nanomaterials: silica nanomaterials 
and polythiophenes.  
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2.1 SILICA NANOMATERIALS 
Silica is one of the most abundant materials on earth, and occurs in its natural form as 
quarts sand, rocks, and clays. These primary raw materials are chemically treated to 
produce direct silica sources, such as sodium silicate, silicon tetrachloride, and 
alkoxysilane. These are in turn used to produce synthetic silica products, such as silica 
gel, precipitated silica, silica sol/colloidal silica, and fumed silica 
19
. Moreover, the 
silica surface is populated with Si-OH groups known as silanol groups (some of these 
silanol groups ionize to Si-O
-
 upon contact with water), which can be used to 
functionalize the surface with a variety of desired modifications 
20
. Synthetic and 
engineered silica nanomaterials have numerous applications in various areas such as 
electronics, sensor technologies, coatings and additives, and are also of considerable 
interests for diagnostic and therapeutic applications in medicine 
19
. Due to their 
chemical properties and biocompatibility, they are also commonly applied as surface 
coatings to other functional materials 
21
. 
 
Mesoporous silica nanomaterials, a type of silica materials exhibiting porous structures 
on the mesoscopic scale (2-50 nm), offer attractive properties for loading and releasing 
large quantities of biomedical agents such as drugs, genes and proteins 
22, 23
. Figure 2 
shows the mesoporous structures of these materials by means of transmission electron 
microscopy (TEM). Mesoporous structures are typically synthesized by introducing 
self-assembling micellar templates to a sol-gel synthesis of silica 
24
. The organic 
micellar templates (e.g. amphiphilic surfactants) can self-assemble into different 
structures (cubic, hexagonal, cylindrical) and are removed by thermal calcination or 
solvent extraction after synthesis of silica species, revealing the mesoscale pores 
supported by a silica wall 
24-26
. This results in materials with very high surface area (> 
1000 m
2
/g) that is advantageous for accommodating large amounts of therapeutic load.  
 
 
 
 
 
 
 
 
 
 
Figure 2. TEM images of common mesoporous structures. Courtesy: Dr. Alfonso 
Garcia-Bennett. 
 
 
2.2 POLYTHIOPHENES 
Polythiophenes constitute an interesting class of synthetic polymer materials, resulting 
from the polymerization of thiophenes (Figure 3). They can be synthesized chemically 
or electrochemically 
27, 28
. Synthetic polymers have traditionally been regarded as poor 
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electronic conductors and are often used as insulators. However, polymers can be made 
electrically conductive when electrons are added or removed from the conjugated #-
orbitals via a process called doping. The discovery of conductive polymers was 
awarded the Nobel Prize in chemistry in 2000 
29
. Moreover, conductivity is not the only 
interesting property resulting from electron delocalization, the same mechanism also 
confer optical properties. Polythiophenes are utilized for a number of applications such 
as conductive films, electrochemical transistors, as well as diagnostic and imaging tools 
30, 31
.  
 
 
 
         
 
 
Figure 3. The chemical structure of polythiophenes. 
 
 
2.3 PHYSICOCHEMICAL PROPERTIES OF NANOMATERIALS IN 
RELATION TO THEIR PHARMACOKINETIC PROFILES 
The behavior of nanomaterials in vivo is the result of a combination of many different 
factors, including their size, surface charge, porosity, shape, mechanical flexibility, 
biodegradability, and so on. Therefore, the following discussion is only of reference 
and not of absolute term. 
 
Size.  
 
Particle size has a significant impact on their blood circulation time 
32
. Very small 
particles (< 10 nm) are quickly excreted through the kidneys whereas large particles (> 
200 nm) are easily recognized and cleared by phagocytes of the RES. The optimal 
particle size for intravenous therapeutics is suggested to be around 100 nm owing to 
their extended blood circulation time, whereas the upper limit would be around 1.5 µm 
since larger particles are expected to clog capillaries 
33
. Due to the EPR effect of tumor 
tissues, particles ranging from 100-200 nm in size accumulate more readily in solid 
tumors 
34
. Smaller particles are more prone to cross biological barriers, and it has been 
shown that particles less than 11.7 nm have the potential to cross the tight junctions of 
the blood brain barrier in rodents 
35
. The excretion of injected particles were also shown 
to be size-dependent, with the 50 nm particles excreting faster than 100 and 200 nm 
fluorescence labelled silica particles via the urine and bile 
36
. 
 
Surface charge/hydrophobicity.  
 
Surface charge is an important factor that affects the behavior of nanoparticles. 
Generally, the RES has better clearance of positively charged particles than negatively 
charged particles, with neutrally charged particles being the least affected and therefore 
having the longest blood circulation time 
33
. Hydrophobic particles tend to have more 
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interactions with proteins and cells than their hydrophilic counterparts. A hydrophilic 
polymer extended surface such as polyethylene glycol (PEG) is therefore often used to 
shield nanoparticles from immune responses 
33
. 
 
Porosity.  
 
Materials with pore diameters less than 2 nm are termed microporous, with pore 
diameters between 2-50 nm are termed mesoporous, and with pore diameters larger 
than 50 nm are termed macroporous. Mesoporous materials are most useful for 
biomedical applications since a large proportion of therapeutic agents are within this 
size range. Porous materials have a significantly higher total surface area but a lower 
external surface area than their nonporous counterparts, potentially affecting their 
interactions with biological systems 
37
. Intravenous injections in immune-competent 
mice showed that mesoporous silica nanoparticles exhibited a higher accumulation in 
the lung than nonporous silica nanoparticles of similar size. These mesoporous 
nanoparticles were transiently associated with the lung and then redistributed out of this 
organ without significant internalization 
38
.  
 
Shape.  
 
Shape also plays a significant role for the biological behaviors of nanomaterials. 
Particles with different shapes experience distinct hydrodynamic forces in the blood 
flow. Non-spherical particles (compared to spherical particles) have a higher tendency 
to move towards the blood vessel walls, referred to as margination effect 
33
. Shape is 
also important during the filtration process through the spleen and kidney, as well as 
during phagocytosis 
33
.  
 
Mechanical flexibility.  
 
The rigidity of particles can influence their ability to pass through blood vessels, as well 
as through the filters of the spleen and kidney. Rigid particles are also taken up to a 
higher extent by macrophages compared to their soft and flexible counterparts 
33
.  
 
Biodegradability.  
 
Similar to the size-dependency, nanomaterials biodegraded into small molecular weight 
components exert different pharmacokinetic profiles. For example, silicic acid, the 
dissolution product of silica (at high pH), can be efficiently excreted from the human 
body through urine 
39
.   
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3 BIOCOMPATIBILITY ASSESSMENT 
 
It is of vital importance to assess the biocompatibility of nanomaterials before they can 
be used for medical applications. Moreover, understanding the relationship between the 
physicochemical properties and the biocompatibility/toxicity of nanomaterials will 
further assist the rationale design of these materials with improved biocompatibility.  
 
 
3.1 TARGET ORGAN BIOCOMPATIBILITY/TOXICITY 
Common routes of administration for nanomaterial-based delivery systems are through 
systemic injection, inhalation, or oral absorption. Systemic injection results in direct 
exposure to the circulation system, whereas inhalation or orally administered agents 
may also end up in the blood stream owing to the ability of nanoparticles to cross 
biological barriers 
40
. Indeed, it has been shown that following inhalation, nanoparticles 
are capable of crossing the alveolar-capillary barrier and entering the bloodstream, 
especially in the presence of inflammation as it increases the permeability of the 
endothelium 
41
. Similarly, nanoparticles can enter the circulation and subsequently be 
distributed to other tissues/organs following gastrointestinal absorption 
42
. Therefore it 
is of primary importance to understand the blood biocompatibility (red blood cell 
hemolysis, blood coagulation, interactions with white blood cells, serum biochemistry) 
of nanomaterials.  
 
In studies with mice, it was shown that nanoparticles are taken up extensively by the 
liver and spleen, where they are passively entrapped in the fenestrations of the 
endothelium of these organs 
38
. Physical sequestration accumulates particles in these 
organs, such as liver, the powerhouse of biotransformation and immune clearance 
43
. 
Enzymatic reactions (e.g. Phase I and II) in the liver may result in detoxification or 
aggravated hepatoxicity 
43
. Therefore, the impact of liver enzymes constitutes an 
interesting aspect for the biocompatibility/toxicity investigations of nanomaterials as 
drug and gene delivery systems. 
 
For a more comprehensive assessment of the biocompatibility/toxicity of 
nanomaterials, please refer to an excellent review by Zhao and Castranova 
44
. 
 
 
3.2 MECHANISMS OF POTENTIAL CYTOTOXIC EFFECTS 
As the saying goes, ‘the dose makes the poison’. In biocompatibility/toxicity 
evaluations, it is important to investigate dose-response relationships as well as high 
dose scenarios where toxic responses are revealed, as these can be used to determine 
appropriate dosages and acceptable limits 
45
. It is also important to keep in mind that, 
the same substance may have different mechanisms of action depending on the 
magnitude of the exposure 
46
. 
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The imbalance between reactive oxygen species (ROS) and antioxidant defense termed 
oxidative stress has been proposed to be the dominant paradigm for potential 
nanoparticle-induced toxicity at the cellular level 
47
, although not all studies confirm 
this general notion 
48
. ROS can be generated from the reactive surface of some 
nanoparticles (e.g. the photocatalytic properties of TiO2 nanoparticles) 
49
, the 
mitochondria as the main intracellular ROS generating source of eukaryotic organisms, 
and/or the multi-component enzyme NADPH oxidase as the main ROS generating 
machinery of phagocytic cells against foreign invaders 
50
. Depending on the level of 
oxidative stress, cellular responses may vary from adaptation and damage repair to 
senescence and cell death (Figure 4). At low levels of oxidative stress, the cell or 
organism adapts by up-regulating their defence systems. Increased levels of oxidative 
stress may switch mitotic cells into senescence cells that can survive for longer periods. 
Failure to cope with such oxidative stress may cause cells to die through apoptosis, 
which protects surrounding tissues from further damage. Under more severe conditions 
of oxidative stress, cells may undergo necrotic cell death exposing surrounding tissues 
to further inflammatory responses 
46
. Important pathways involved in the regulation of 
oxidative stress include mitogen-activated protein kinases (MAPK), nuclear factor 
kappa B (NF-!B), and nuclear factor like 2 (Nrf2) signalling pathways. Lipids, proteins 
and DNA are primary cellular targets of oxidative stress. Furthermore, damages from 
oxidative stress have implications in aging, cardiovascular diseases, neurodegenerative 
diseases, cancer, and so on 
51
.   
              
 
Figure 4. The hierarchical model of oxidative stress. Adapted from Meng et al., 2009 
52
. 
 
On the other hand, other mechanisms of nanoparticle-induced toxicity such as 
nanoparticle-induced inflammation and/or genotoxicity have also been observed 
53, 54
. 
The mechanisms of nanoparticle-induced oxidative stress, and whether oxidative stress 
is the primary cause of cellular destruction or rather stem from the injury triggered by 
other mechanisms, remain to be interesting areas of investigation 
55
. 
 
 
3.3 BIOLOGICAL DEFENSE SYSTEMS 
Evolutionary forces have shaped biological systems with a multitude of physical and 
chemical defense systems. Here, two of these defense systems, blood plasma/serum and 
liver enzymes, are highlighted.  
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3.3.1 Blood plasma/serum  
Blood plasma is the blood fluid that holds blood cells in suspension. It contributes to 
about 55% of the total volume of whole blood. Blood serum is blood plasma without 
clotting factors such as fibrinogen. Blood plasma/serum contains glucose, electrolytes, 
hormones, antigens, and thousands of different proteins (whose abundance varies by 
twelve orders of magnitude 
56
), many of which serve important functions to defend the 
body against potential dangers. For example, metallothioneins sequester heavy metals 
through their cysteine residues 
57
; albumins exhibit important antioxidant properties 
58
.  
 
This thesis focuses on the so-called plasma/serum ‘corona’ over particle surfaces. Upon 
contact with biological fluids such as blood plasma/serum, particles are immediately 
coated by the adsorption of biomolecules such as proteins and lipids, forming a 
‘corona’ over the particle surface 
59
. The biological corona has been suggested to be 
determined by the size and surface properties of the original particle surface 
60
. A 
quantitative approach to characterize surface adsorption energy included parameters 
such as hydrophobicity, hydrogen bonds, polarity/polarizability, and lone-pair 
electrons, to simulate the interaction forces of nanomaterials in biological systems 
61
. 
Studies have also shown that the corona can be loosely divided into two components: a 
long-lived ‘hard’ corona, with a durable coating of high affinity proteins bound for at 
least a few hours over the bare nanoparticle surface; and a short-lived ‘soft’ corona with 
typically short exchange times and loosely bound proteins 
56, 60
. Examples of the hard 
corona proteins include albumin, apolipoproteins, glycoproteins, plasminogens, 
fibrinogens, and complement factors 
56
. The protein corona is a dynamic phenomenon: 
proteins in the corona not only exchange with proteins in the biological fluids in a static 
environment 
59
; the protein corona also evolves when particles navigate in the body and 
pass from one biological fluid to another 
62
. The surface of nanoparticles is therefore 
modified by a dynamic layer of biological factors, which affect their recognition, 
behavior, and toxicity 
63
.  
 
3.3.2 Liver enzymes 
Liver is the most important organ for the detoxification of xenobiotics by enzymes. 
Phase I enzymes, particularly cytochrome P450, catalyze the oxidative and reductive 
reactions of xenobiotics. Many products of phase I reactions then become substrates of 
phase II enzymes, which catalyze conjugation reactions to convert their substrates into 
more polar products in order to facilitate their excretion through the urine and bile 
43
.  
 
Microsomal glutathione transferase 1 (MGST1), a phase II enzyme extensively studied 
for its ability to detoxify substances of both endogenous and exogenous origin, is 
highlighted here 
64
. In cells, it is primarily located in the endoplasmic reticulum and the 
outer mitochondrial membranes 
65
. The structure of MGST1 is a homotrimer, each 
subunit with a molecular weight of 17.3kDa and a binding site for glutathione (GSH) 
66
. Its active site is located at the residue cysteine 49, where covalent binding to GSH 
induces conformational changes and thereby activates the enzyme 
67
. MGST1 has 
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broad substrate specificity, as the enzyme has been shown to be activated by N-
ethylmaleimide (NEM) 
67
, trypsin 
68
, radiation 
69
, heat 
70
, and oxidative stress 
71, 72
. 
MGST1 displays both glutathione transferase and glutathione peroxidase activities. 
Using its glutathione transferase activity, MGST1 catalyzes the conjugation of GSH to 
its electrophilic hydrophobic substrate and converts it into more polar metabolites 
64
. 
The reaction is the first out of four steps in the mercapturic acid pathway 
73
. These 
GSH-conjugates are then transported out of the cells via transmembrane multidrug 
resistance proteins (MRP) and subsequently excreted out of the body 
74
. Using its 
glutathione peroxidase activity, MGST1 catalyzes the GSH dependent reduction of 
lipophilic hydroperoxides and lipid hydroperoxides 
67, 75, 76
 (Equation 1).  
 
Glutathione peroxidase activity: 2GSH + ROOH $ GSSG + ROH + H2O                 (1) 
 
The glutathione peroxidase activity of MGST1 plays an important role in the context of 
oxidative stress. MGST1 has been shown to be activated by oxidative stress both on the 
transcriptional level as well as by protein modification 
64
.  It can protect cells against 
lipid peroxidation by displaying its glutathione peroxidase activity towards lipid 
hydroperoxides and lipid ozonides 
75, 76
. It can also protect against downstream 
products of lipid peroxidation by conjugation of their toxic end products, e.g 4-
hydroxyalk-2-enals 
76
. Indeed, MGST1 has been shown to protect against injury from 
oxidative stress in HEK293 cells 
77
, MCF7 cells 
78, 79
, and retinal pigment epithelium 
77
. 
Interestingly, an increase in the expression of MGST1 has been observed with aging 
80
, 
chronic obstructive pulmonary disease 
81
, and various tumors 
82-86
, all of which appear 
to be associated with increased oxidative stress. Up-regulation of MGST1 mRNA and 
protein synthesis has been suggested to be an early stage biomarker of various diseases 
associated with oxidative stress 
86-88
. 
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4 GENE DELIVERY  
 
Gene therapy is the therapeutic approach aiming at the permanent, or transient, 
correction of a gene defect by intracellular delivery of nucleic acids. Major therapeutic 
targets for gene therapy include cancer, monogenic hereditary diseases, infectious 
diseases and respiratory diseases 
89-93
. However, delivery issues remain one of the most 
important bottlenecks in the development of gene therapy 
93
. Gene vaccination is 
another application of gene delivery, where the introduction of antigen encoding genes 
into target cells triggers cellular and humoral (antibody) immune responses 
94
.  
 
 
4.1 GENE DELIVERY VECTORS 
Initial delivery of genes exploits the natural mechanisms of viruses as delivery vehicles. 
Despite the higher delivery efficiency of viral vectors, they often suffer from toxicity 
and immunogenicity-related issues 
95
. Non-viral vectors are emerging as safer 
alternatives to viral vectors. Major research efforts are directed towards understanding 
the mechanisms associated with the enhancement of gene delivery efficiency 
95, 96
 as 
well as the development of safe and efficient novel gene delivery vectors 
97
.  
 
Classical non-viral vectors include lipids, cationic polymers and cell penetrating 
peptides, whereas more recent applications explore the use of nanomaterials such as 
silica nanoparticles, gold nanoparticles, magnetic nanoparticles, and carbon nanotubes 
for gene delivery 
93, 98
. Endogenous nano-size vesicles, so called exosomes, have also 
been explored as delivery vehicles 
99
. Moreover, combined approaches are being 
investigated in the pursuit of multifunctional platforms to improve their performance in 
targeting and efficiency 
100, 101
. 
 
In general, delivery vectors shall be able to carry out the following steps: (1) form 
stable complexes with nucleic acids, (2) enter target cells by endocytosis-mediated 
uptake, (3) escape the endosomes to reach the cells’ cytoplasm, (4) in certain cases, 
such as delivery of DNA, the complexes or the released nucleic acids enter the cells’ 
nucleus, and (5) execute targeted and efficient gene regulation 
29
. These are depicted in 
Figure 5 and explained in more details in the following sections. 
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Figure 5. Critical steps in gene delivery: (1) formation of stable complexes between the 
delivery vectors and oligonucleotides; (2) endocytosis mediated uptake of the stable 
complexes; (3) endosomal escape; (4) oligonucleotides release; (5) nuclear uptake of 
oligonucleotides and their subsequent replication with host DNA; (6) transcription to 
mRNA; (7) translation to protein. 
  
 
4.2 INTRACELLULAR UPTAKE AND TRAFFICKING 
Complex formation.  
 
Gene delivery vectors often bear cationic charges to enable electrostatic interactions 
with anionic nucleic acids. Following interactions with the vectors, the extended 
nucleic acids are reversibly converted into compact particles, known as nucleic acid 
condensation 
102
. Thermodynamic analysis suggested that multivalent cations present 
on the vector associate with the anionic nucleic acid phosphate groups, which causes 
local bending of the nucleic acid (forming rods and toroid-like structures) and results in 
a reduction of entropy 
103
. This process often makes nucleic acids more stable and 
resistant towards degradation by serum nucleases 
104
.  
 
Endocytosis.  
 
Endocytosis refers to the cellular uptake of macromolecules and solutes into 
membrane-bound vesicles derived by the invagination and pinching off of pieces of the 
cell plasma membrane. In non-phagocytic cells, there are at least four different 
pathways: clathrin-mediated endocytosis, caveolin-mediated endocytosis, 
macropinocytosis, and clathrin/caveolin-independent endocytosis. They differ in the 
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composition and size of the membrane vesicle, as well as the fate of the internalized 
particles. Most of these pathways can involve receptor-ligand interactions. 
105
. 
 
The ‘trojan horse’ of delivery.  
 
For cationic lipid-based vehicles, nucleic acids are thought to be released from 
endosomes into the cytoplasm through exchange and fusion between lipids in the 
liposome and the endosomal membrane 
106
. A different model has been proposed for 
the endosomal escape of cationic polymer-based vehicles, such as polyethylenimine 
(PEI). According to the ‘proton sponge hypothesis’, the unsaturated amino groups on 
these vectors sequester protons, and protons are therefore continuously pumped into the 
endosome promoting passive entry of chloride ions and subsequent osmotic swelling 
and endosome rupture 
107
. Disassembly of nucleic acids from the delivery vectors can 
occur after endosomal release in the cytosol or in the nucleus 
108-110
. For novel vectors, 
such as inorganic nanoparticles, the mechanisms of cellular uptake and endosomal 
escape are important areas of investigation. 
 
Nuclear transport.  
 
The transport of certain vector-nucleic acid complexes or released nucleic acids across 
the nuclear envelope occurs through the nuclear pores. While very small particles can 
freely diffuse through the nuclear pore, larger molecules enter the nucleus through a 
nuclear pore complex (NPC) that can be enlarged to about 55 nm in diameter 
17
. 
Studies indicate that DNA can traverse the NPC by itself in a process driven by 
nucleotide triphosphate hydrolysis and/or energy released upon binding to nuclear 
components 
111, 112
. Moreover, nuclear localization signals are common strategies used 
to facilitate nuclear delivery 
113
. 
 
 
4.3 GENE REGULATION 
Gene regulation is the process that cells and viruses use to regulate the expression of 
genes into gene products. The regulation of gene expression by exogenous delivery of 
nucleic acids includes plasmid DNA (pDNA), small interference RNA (siRNA), 
antisense oligonucleotides, splice correction oligonucleotides, and so on. Delivery of 
pDNA and siRNA represents two complementary approaches to restore or silence a 
specific cellular function 
114
. The completion of the human genome sequencing in 2001 
115, 116
, enabled groundbreaking progress for gene regulation. 
 
Circular double-stranded pDNA molecules are to be introduced into the cell nucleus. 
Besides the therapeutic gene(s), pDNA may also contain other sequences such as 
promoter/enhancer elements. For example, tissue-specific promoter sequences can be 
used to restrict the gene expression to specific target tissues 
117
.  
 
Double-stranded RNA sequences of 21-24 nucleotides, known as siRNA, are 
introduced into the cell cytoplasm to allow sequence-specific gene silencing. In the 
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cytosol, siRNA binds to a protein complex termed the RNA-induced silencing complex 
(RISC), which mediates the unwinding of the siRNA duplex to bind to the target 
mRNA 
118
. 
 
Luciferase and green fluorescent protein (GFP) are often used as reporter genes for the 
proof of principle of gene regulation due to their sensitivity and ease of detection. 
However, restoring or silencing of functional genes is the main purpose of gene 
therapy. The major types of genes targeted in gene therapy clinical trials are listed in 
Table 3. 
 
Table 3. Types of genes regulated in gene therapy clinical trials in 2007 
119
.  
 
Gene types Example Percentage Number 
Antigen ALVAC-HIV 20.3% 266 
Cytokine IL-2 18.9% 247 
Tumor suppressor p53 12% 157 
Growth factor GM-CSF 8.2% 107 
Suicide Survivin-T34A 8.2% 107 
Deficiency SCID-X1 7.9% 103 
Receptor TCR 5.1% 67 
Marker CD4+ 4.1% 54 
Replication 
inhibitor 
Ribozyme 3.7% 48 
Other P-glycoprotein  11.5% 153 
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5 PRESENT INVESTIGATIONS 
 
5.1 AIMS OF THE THESIS 
The overall objective of this thesis is to investigate the biocompatibility of synthetic 
nanomaterials of medical relevance and to explore their applications in gene delivery. 
The specific aims in papers I-IV are: 
 
• I: to study the blood cell toxicity/biocompatibility of silica nanoparticles, as 
well as plasma protection mechanisms; 
 
• II: to study the cytotoxicity/biocompatibility and oxidative stress induced by 
synthetic nanoparticles, as well as protection mechanisms by the liver phase 
II detoxification enzyme MGST1; 
 
• III: to explore the applications of amino-modified silica nanoparticles as 
vectors for the delivery of pDNA;  
 
• IV: to explore the applications of amino acid-modified polythiophenes as 
vectors for the delivery of siRNA.  
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5.2 METHODOLOGY 
Cell models and methods used in papers I-IV are described in detail in the respective 
‘Materials and methods’ sections. Below follows an overview of each cell model and 
method with references to the paper(s) in which they are used:  
 
 
Cell models: 
 
In Paper I, red blood cells freshly isolated from human volunteers and HL-60 human 
promyelocytic leukemia cells were used to study the ability of silica nanoparticles to 
induce permeability in biological membranes (hemolysis and cytotoxicity).  
 
In Paper II, MCF-7 human breast carcinoma cells, with and without overexpression of 
rat MGST1, were used as model systems to investigate whether MGST1 could protect 
against the cytotoxicity of SiO2, TiO2, CeO2, and ZnO nanoparticles. Human breast 
cells rather than hepatocytes were used, because these MCF-7 human breast carcinoma 
cells have low expression of MGST1 as well as cytosolic glutathione transferases 
(GSTs). The sense cells were stably transfected with a vector that contains rat MGST1, 
and the antisense cells with the antisense orientation of rat MGST1. The overexpression 
level of rat MGST1 in sense cells is ten times less than the expression level in the liver 
120
.  
 
In Paper III, MCF-7 human breast carcinoma cells were used to investigate the cellular 
delivery of pDNA using silica nanoparticles as vectors.  
 
In Paper IV, the human osteosarcoma cells U2-OS, either wild-type or stably 
transfected with a luciferase-encoding plasmid, were used to investigate the cellular 
delivery of luciferase siRNA using polythiophenes as vectors. Human cervical 
carcinoma HeLa cells were used for live-cell fluorescence microscopy, as the U2-OS 
cells contain a GFP construct that could interfere with the absorption and fluorescence 
emission of poly(3-[(S)-5-amino-5-methoxycarboxyl-3-oxapentyl]-2,5-thiophenylene 
hydrochloride) (POMT). 
 
 
Methods: 
 
Bicinchoninic acid (BCA) protein 
assay [I,II] 
 
Brunauer, Emmet and Teller method 
(BET) [I] 
 
C11-BODIPY
581/591 [II] 
 
A biochemical assay for determining the 
concentration of protein in solution. 
 
Calculates the surface areas of solids by 
physical adsorption of gas molecules. 
 
A fluorescent probe of lipid 
peroxidation. 
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Circular dichroism (CD) 
spectroscopy [IV] 
 
 
 
1-chloro-2,4-dinitrobenzene (CDNB) 
assay [II] 
 
Chloroquine (CQ) [IV] 
 
 
Colony formation efficiency (CFE) 
assay [II,III] 
 
Confocal laser scanning microscopy 
(CLSM) [IV] 
 
Dichlorofluorescein diacetate 
(DCFH-DA) [I,II] 
 
3-(4,5-dimethythiazol-. 2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) 
assay [II,III] 
 
Dynamic light scattering (DLS) 
[I,II,III] 
 
 
Fluorescein isothiocyanate (FITC) 
labelling of nanoparticles [II] 
 
Formamidopyrimidine DNA- 
glycosylase (FPG)-comet assay [II] 
 
Flow cytometry (FACS) [II] 
 
 
 
Fluorescence microscopy analysis [II] 
 
 
Gel retardation assay [III] 
 
 
Hemolysis assay [I,IV] 
The measurement of differential 
absorption of circularly polarized light 
exhibits optically active chiral 
molecules. 
 
A spectrophotometric assay to measure 
GST activity. 
 
Leads to swelling and bursting of 
endosomes. 
 
Measures cell colonies as index of long-
term viability or proliferation ability. 
 
Optical imaging technique enabling 
scanning through cells. 
 
A fluorescence probe that measures 
hydrogen peroxide (H2O2) production. 
 
A colorimetric assay that measures the 
activity of a mitochondrial enzyme 
which is crucial for cell viability.  
 
Measures the size distribution of small 
particles in suspension by means of light 
scattering. 
 
The conjugation of fluorochrome for 
tracking of nanoparticles.  
 
Detection of oxidative DNA damage 
using a gel electrophoresis based assay. 
 
Laser based analysis of cells in flow 
using fluorochrome conjugated 
antibodies. 
 
Optical microscope that uses 
fluorescence to generate images. 
 
Affinity electrophoresis to study nucleic 
acid interactions with other substances.  
 
Assay for the rupture of red blood cells. 
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Inductively coupled plasma (ICP) 
analysis [II] 
 
Lactate dehydrogenase (LDH) assay 
[I,II] 
 
Limulus Amebocyte Lysate (LAL) 
endochrome assay [II] 
 
Luciferase assay [III,IV] 
 
 
Mitochondrial respiration [II] 
 
 
MitoSOX
TM [II] 
 
 
Newport Green
TM
 DCF [II] 
 
 
Nanoparticle tracking analysis (NTA) 
[IV] 
 
 
Scanning electron microscopy (SEM) 
[I] 
 
 
Statistical analyses [I,II,III,IV] 
 
 
Surface modification [I] 
 
 
Tetramethylrhodamine ethyl ester 
(TMRE) [II] 
 
ThioGlo% [II] 
 
 
Transmission electron microscopy 
(TEM) [I,II,III]  
 
Detection of metal and non-metal ions 
by electromagnetic induction. 
 
A colorimetric assay for the release of 
LDH as measure of membrane integrity.  
 
Enzyme based test to detect 
lipopolysaccharide (LPS) in solution. 
 
A reporter assay to assess gene 
regulation activity in transfected cells. 
 
Measurement of oxygen concentration as 
a function of mitochondrial respiration. 
 
A fluorescent probe that measures 
mitochondrial superoxide production. 
 
A fluorescent probe indicating the 
presence of metal ions. 
 
Combines laser light scattering 
microscopy with a charge-couple device 
camera for particle sizing in solution. 
 
Provides images of a sample surface by 
scanning it with a high-energy beam of 
electrons. 
 
Data analyses using methods of 
probability theory. 
 
Acid/base treatment of silica surface to 
enable modification of silanol groups. 
 
A fluorescent dye that measures 
mitochondrial membrane potential. 
 
A fluorescent dye that measures active 
thiols. 
 
Microscopic technique using a beam of 
electrons instead of light. 
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Trypan blue exclusion [I]  
 
 
Western blot analysis [II]  
 
 
 
X-ray diffraction (XRD) [I] 
 
 
X-ray photon electron spectroscopy 
[I] 
 
 
Zeta-potential [I,II,III] 
 
 
Dye exclusion test to measure cell 
membrane integrity. 
 
Gel electrophoretic separation of 
proteins and subsequent transfer to 
membranes for antibody detection. 
 
Tool to investigate structures on the 
atomic scale. 
 
Spectroscopic technique that measures 
the elemental composition and electronic 
state of the elements within a material. 
 
Measures the electrokinetic potential in 
colloidal systems.
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5.3 RESULTS 
Paper I. The hemolytic properties of synthetic nano- and porous- silica particles: 
the effect of surface properties and the protection by the plasma corona. 
 
In Paper I, the hemolytic properties of amorphous silica nanoparticles with primary 
sizes of 7-14 nm (hydrophilic versus hydrophobic), 5-15 nm, 20 nm, and 50 nm, and 
model meso/macroporous silica particles with pore diameters of 40 nm and 170 nm 
were investigated. A crystalline silica sample (0.5-10 µm) was included for 
benchmarking purposes. The results showed that the temperature and chosen solution 
could affect the hemolytic properties of silica particles, emphasizing the importance of 
hemolysis testing at physiological conditions. Although no single parameter (such as 
size, surface charge, total surface area) alone was observed to correlate significantly 
with hemolysis, surface modification experiments clearly demonstrate that surface 
properties are linked to the hemolytic activities of these particles. Moreover, 
hydrophobic modified particles completely inhibited the hemolytic activity of pristine 
hydrophilic particles. Furthermore, a significant correlation was observed between the 
hemolytic profile of red blood cells and the cytotoxicity profile of human 
promyelocytic leukemia HL-60 cells induced by nano- and porous- silica particles, 
suggesting that silica particles potentially induce membrane permeability through a 
universal mechanism of action. Importantly, the generated results suggest that the 
protective effect of plasma towards silica nanoparticle-induced hemolysis as well as 
cytotoxicity is primarily due to the protein/lipid corona shielding the silica particle 
surface rather than the functional activities of plasma (Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Effect of heat-denatured plasma or plasma corona on hemolysis and 
cytotoxicity induced by silica particles: (A) hemolysis and (B) cytotoxicity induced by 
2 mg/mL silica particles. n=3-4. All values were significantly different (p<0.001) from 
those without plasma or corona. 
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Paper II. Microsomal glutathione transferase 1 protects against toxicity induced 
by silica nanoparticles but not by zinc oxide nanoparticles. 
 
In Paper II, the cytotoxicity and oxidative stress induced by TiO2 (rutile/anatase), CeO2, 
SiO2 (amorphous) and ZnO nanoparticles of similar size (primary size less than 30 nm), 
was evaluated in human breast carcinoma MCF-7 cells with or without overexpression 
of MGST1. In the absence of serum, SiO2 and ZnO nanoparticles caused dose- and 
time-dependent toxicity whereas no obvious cytotoxic effects were induced by TiO2 
and CeO2 nanoparticles. Four additional SiO2 nanoparticles were tested and three out of 
four also showed pronounced cytotoxic effects. Notably, overexpression of MGST1 
reversed the cytotoxicity of two of the SiO2 nanoparticles tested but did not protect 
cells against ZnO-induced cytotoxic effects (Figure 7), suggesting different underlying 
mechanisms of action for the different nanoparticles. Moreover, the cytotoxicity of 
SiO2 nanoparticles was dramatically reduced whereas that of ZnO nanoparticles was 
only slightly reduced in the presence of serum, further suggesting different interactions 
between serum and the different nanoparticles. The results suggest a prominent role of 
lipid peroxidation in SiO2 nanoparticle-induced cellular damage, and the role of zinc 
ion dissolution for ZnO nanoparticle-induced cellular damage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. MGST1 protects against SiO2 nanoparticle-induced cytotoxicity but not ZnO 
nanoparticle-induced cytotoxicity. MGST1 protection against nanoparticle-induced 
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cytotoxicity at 24 h was assessed using MTT assay for assessment of metabolic 
activity (A, B), LDH assay to monitor cell membrane damage (C, D), and CFE assay 
to monitor the late effects of particle exposure (24 h exposure, followed by a further 7 
day incubation) (E, F). MGST1 overexpressing cells are indicated by filled squares 
and solid line, antisense transfected cells by triangles and dashed line, and MCF-7 
wild-type cells by diamonds and dotted line. The results are expressed as mean values 
± standard deviations (n = 3-4); *<0.05, **<0.01, ***<0.01.  
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Paper III. Amino-modified silica nanoparticles as non-viral vectors for the 
delivery of plasmid DNA.  
 
In Paper III, the applications of amino-functionalized silica nanoparticles for gene 
delivery are investigated. In this study, amino-modified silica nanoparticles of primary 
size 20-50 nm were used to successfully deliver luciferase-encoding pDNA into human 
breast carcinoma MCF-7 cells, as confirmed by an increase in luciferase gene 
expression. The delivery efficiency was higher using amino-modified nonporous silica 
particles as compared to amino-modified mesoporous silica particles (pore diameter of 
2.4 nm), with similar size and loading of amino groups (wt%) (Figure 8). Moreover, the 
delivery efficiency was higher in the presence of serum than in the absence of serum. 
The binding of pDNA to amino-modified silica nanoparticles was confirmed with a gel 
retardation assay, and TEM images revealed the intracellular localization of these 
particle-DNA complexes to be in membrane-enclosed vesicles. Particle vectors alone as 
well as particle-DNA complexes showed good biocompatibility, with the nonporous 
particles/particle-DNA complexes slightly more toxic than their mesoporous 
counterparts. And both particles/particle-DNA complexes were slightly more toxic in 
the absence of serum than in the presence of serum.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Delivery of luciferase expressing plasmid using amino-functionalized 
nonporous and mesoporous silica particles in MCF-7 cells in the presence of serum. 
n=3. *<0.05, **<0.01, ***<0.001. 
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Paper IV. Delivery of small interfering RNA using an amino acid-modified 
polythiophene. 
 
In Paper IV, the polythiophenes (namely POMT and POWT) were used as vectors for 
the cellular delivery of siRNA. Human osteosarcoma U2-OS cells, wildtype or stably 
transfected with a luciferase-encoding plasmid, were used to confirm the delivery of 
anti-luciferase siRNA upon non-covalent complex formation with polythiophenes. 
Notably, the cationic POMT was highly efficient in the delivery of siRNA whereas its 
zwitteronic analogue POWT was considerably less efficient, underscoring the 
importance of polymer cationicity in the delivery efficiency of the vector. Figure 9 
demonstrates the successful delivery of anti-luciferase siRNA using POMT. 
Furthermore, mechanistic and biocompatibility studies were performed for POMT. Pre-
incubation of siRNA:POMT at 4°C substantially reduced delivery efficiency, implying 
that the siRNA:POMT complexes triggered energy-dependent uptake into mammalian 
cells. Pre-incubation of siRNA:POMT with chloroquine (which prevents endosomal 
acidification) did not enhance delivery efficiency, suggesting that endosomal escape 
was not a limiting factor in the delivery process. Circular dichroism spectroscopy 
indicated that POMT maintained a helical conformation even after complexation with 
siRNA, a feature that could potentially explain their efficient cellular internalization 
and endosomal escape. Moreover, HeLa cells were used to probe co-localization of 
Cy5-labeled siRNA and the autofluorescent POMT by live-cell fluorescence 
microscopy. The results suggested potential co-localization of Cy5-siRNA and POMT 
directly after transfection, which decreased after 24 h. Biocompatibility studies showed 
that siRNA:POMT complexes displayed negligible hemolysis of red blood cells 
(medical acceptance level is less than 5%) up to 24 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. The optimal molar ratio for delivery of anti-luciferase siRNA, assayed at an 
siRNA concentration of 50 nM, was 1:50 siRNA:POMT. An unrelated siRNA at the 
same concentration did not induce any significant silencing at any molar ratio.  
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5.4 GENERAL DISCUSSION 
 
Physical, chemical and biological differences between conventional drug/gene and 
nanomedicine therapeutics. 
 
As mentioned in previous sections, nanomaterials offer a number of advantages as 
delivery vectors. Some physical, chemical and biological differences between 
conventional drug/gene pharmaceuticals and nanomedicine therapeutics are highlighted 
in Table 4. In Paper III and Paper IV, it was clearly shown that the pDNA or siRNA 
per se would not be able to execute its effect without the delivery vectors. The Papers 
(I-IV) in this thesis aim to further investigate the safety and efficacy of nanomaterials 
as delivery vectors, as well as factors affecting their behaviors.   
 
Table 4. Comparison between conventional drug/gene and nanomedicine therapeutics. 
 
Characteristics Drugs Genes Nanomedicines 
Synthesis Chemical synthesis Isolated from 
plant/animals or 
synthesized by 
means of genetic 
engineering 
Formation of 
complexes between 
drugs/genes and 
nanovectors 
Molecular weight 
or particle size 
Low molecular 
weight, less than 1 
nm 
High molecular 
weight, usually a 
few nanometers 
High molecular 
weight, usually 
around 1-100 nm  
Physical and 
chemical 
characteristics 
Characteristics of 
well-defined small 
molecular weight 
chemicals 
Complex 
physicochemical 
characteristics (e.g. 
tertiary structure) 
Characteristics of 
material science 
and particle 
science, including 
size, shape, 
mechanical 
properties, etc 
Interactions with 
cells  
Typically diffusion 
once inside the cell 
cytoplasm 
Typically degraded 
by cellular enzymes 
Typically confined 
intracellular 
location 
Interactions with 
the human body 
Poor 
pharmacokinetics 
often lead to major 
side effects 
Typically degraded 
by serum enzymes 
Improved 
pharmacokinetics 
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Physicochemical properties of nanomaterials in relation to their biocompatibility 
and gene delivery efficiency.  
 
The work in this thesis emphasizes the basic understanding of the physicochemical 
properties of nanomaterials in relation to their biocompatibility and gene delivery 
efficiency. Although there is no clear consensus in the literature, some patterns are 
emerging. However, a larger sample size or meta-analysis would be necessary for 
deriving meaningful conclusions from statistical analyses of correlations between their 
physicochemical properties and biological endpoints. Moreover, the physicochemical 
properties of nanomaterials are interdependent (for example, synthesis of well-defined 
nanoparticles with different sizes also results in different surface charges) 
121
, therefore 
computer simulations would be needed to fully appreciate such complex relationships. 
 
 Chemical composition and crystallinity.  
 
Currently, most nano-formulations that already exist on the market for in vivo delivery 
and imaging purposes are lipid and liposome based nanocomposites, polymers and iron 
oxide nanoparticles 
1
. Indeed, chemical composition is among the determining factors 
for the biocompatibility of nanomaterials for biomedical applications. In Papers I-III, 
the use of silica nanomaterials as biocompatible nanomaterials for biomedical 
applications was investigated. In Paper II, amorphous silica nanoparticles were also 
compared to cerium oxide, titanium oxide, and zinc oxide nanoparticles of similar size. 
Results from Paper II and others suggest that amorphous silica is considerably more 
biocompatible compared to many other materials such as zinc oxide, zirconia 
122
, etc. It 
is noteworthy that the crystalline form of silica is rather toxic and not suitable for 
biomedical applications 
122, 123
. In Paper IV, the novel utilities of polythiophenes for 
gene delivery in biomedicine are explored. The toxicity of polythiophenes is not well 
understood, however, it was shown that polythiophene conductive polymers improve 
the biocompatibility of electrodes on primary mouse neurons 
124
. Therefore, chemical 
composition and crystallinity has a strong impact on the biocompatibility of 
nanomaterials. Silica and polythiophene nanomaterials are potentially interesting 
materials for biomedical applications, with mesoporous silica nanoparticles entering the 
stage of preclinical development 
125
. Other potential platforms include gold, magnetic 
nanoparticles, and carbon nanotubes 
1, 18
.  
 
Size.  
 
There is substantial concern of a higher toxic potential at the nanolevel compared to the 
microlevel 
126
, due to the higher proportion of atoms exposed at the surface of 
nanomaterials (compared to bulk materials of the same composition) as well as the 
ability of smaller particles to penetrate deeper into the body. In Paper I, the 
biocompatibility of silica nanomaterials with different size, surface charge, total surface 
area, hydrophobicity, and porosity were compared. These results, although 
inconclusive, suggest that smaller size particles seem to be more hemolytic and 
cytotoxic than larger ones at the same mass dose. Similarly, other studies found size-
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dependent toxicity of amorphous silica particles in vitro and in vivo, with the smaller 
particles being more toxic. For example, smaller particles compared to larger ones were 
shown to be more cytotoxic in various cells by the MTT and LDH assays 
121, 127-129
, 
induce more apoptosis in human keratinocytes HaCaTa cells as detected by the annexin 
V-propidium iodide assay 
130
, and induce more oxidative stress (ROS generation, lipid 
peroxidation and GSH depletion) in human hepatic L-02 cells 
131
. Mice intravenously 
injected with 75 nm silica particles induced liver injury at 30 mg/kg body weight, 
whereas 311 and 830 nm particles had no effect at 100 mg/kg 
132
. Feeding of mice for 
10 weeks (total fed amount of 140 g/kg mice) with 30 nm silica nanoparticles induced 
higher levels of alanine aminotransferase (ALT) and fatty liver patterns compared to 
those of 30 µm silica microparticles (with similar liver retainment) 133. Smaller polymer 
nanoparticles of 45 nm also showed higher cytotoxicity compared to larger 90 nm 
particles in terms of ROS production, adenosine-5'-triphosphate (ATP) depletion, 
tumor necrosis factor (TNF)-& release as well as the reduction of mitochondrial 
membrane potential in different cells 
134
. Interestingly, it was reported that certain 
specific sizes can be substantially toxic, i.e. gold nanoclusters of 1.4 nm are remarkably 
more toxic than marginally smaller or larger gold nanoparticles potentially due to their 
interactions with the major grooves of DNA 
135
.  
 
Higher delivery efficiency in vivo is generally attributed to nanoparticles with a 
diameter around 100 nm, which are capable of circulating in the plasma for a few hours 
rather than seconds to minutes for smaller or larger particles 
4
. In addition to plasma 
circulation time that is a critical prerequisite for delivery, other factors such as cellular 
uptake are also important in governing the delivery efficiency of nanoparticle vectors. 
Size-restrictions affect cellular uptake via different mechanisms of endocytosis 
(clathrin-mediated endocytosis, caveolin-mediated endocytosis, macropinocytosis, and 
clathrin/caveolin-independent endocytosis) 
33, 105
. Nabiev et al. reported that the cell’s 
active transport machinery delivered nonfunctionalized nanocrystals to different 
regions of the cell in a size-specific manner 
136
. He et al. showed that the availability of 
particles to be internalized is better for the smaller particles among particle sizes of 190, 
420, and 1220 nm in various cells 
129
. Lu et al. showed by confocal laser scanning 
microscopy and ICP-MS that cellular uptake in human cervical HeLa cells was optimal 
for silica particles of 50 nm compared to 30, 110, 170 and 280 nm 
137
. Aoyama and co-
workers demonstrated an optimal diameter around 50 nm for the cellular uptake of 
calix[4]-resorcarene-coated macrocyclic glycocluster amphiphiles or quantum dots 138. 
Chan and co-workers also reported 40-50 nm diameter to be optimal for cellular 
internalization of pristine and protein-coated gold nanoparticles 
139, 140
. Theoretical 
models converge on similar conclusions that particles ought to have a minimum 
diameter between 40 and 60 nm in order to achieve effective cellular uptake 
141
. 
Therefore, a delivery system has an optimal physical size in the nanometer range that 
facilitates their cellular binding and uptake (while also depending on other parameters), 
at least in non-phagocytic cells. On the other hand, it was suggested that larger particles 
are also able to enhance gene delivery in cell culture systems in vitro, which might be 
explained by the concentration of nucleic acids at the surface of cultured cells as a 
result of gravity 
142
.  
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Surface charge.  
 
A positively charged surface is generally more toxic than a negatively charged surface, 
due to its potential interactions with many negatively charged biological molecules 
(such as glycolipids and nucleic acids) 
143
. However, Slowing et al. showed that when 
amorphous silica particles were functionalized with carboxylic acid, their zeta-potential 
was similar (from -45.9 to -47.3 mV) but hemolysis was inhibited. This indicates that in 
the case of silica, hemolysis is specific to the silica surface despite the negative surface 
charge. The results in Paper I further points to the specific effects of surface silanol 
groups on the hemolytic and cytotoxic properties of silica particles. Isoda et al. found 
that intravenously administered amino group or carboxyl group modified silica 
nanoparticles were much less toxic than unmodified particles as shown by the level of 
liver injury (serum alanine aminotransferase level, liver hydroxyproline content, 
fibrosis) in mice 
144
. These in vivo findings are also in line with the specific silica 
surface induced toxicity. For many other types of nanomaterials, such as polymers, 
higher positive charges are generally correlated with higher toxicity 
145-147
.  
 
Delivery vectors often carry positive charge to enable ionic complexation with nucleic 
acids. In Paper IV, it was demonstrated that the delivery efficiency of the cationic 
polythiophene was much higher than the zwitteronic polythiophenes. Cellular binding 
and uptake can be achieved either via non-specific adsorptive endocytosis (by 
providing excess positive surface charge) or specifically via receptor-mediated 
endocytosis 
148, 149
. On the other hand, the strength of the ionic interactions between the 
delivery vectors and the nucleic acids can be a limiting factor later during the 
disassembly of the complexes 
150
. In terms of in vivo delivery efficiency, the 
nanoparticle-nucleic acid complex is most desirable to be near neutral in order to avoid 
non-specific interactions with blood components, extracellular matrix and non-target 
cells or tissues in vivo.  
 
Porosity.  
 
Porosity may have an important role in determining the toxicity of nanoparticles. 
Slowing et al. suggested that mesoporous silica particles have reduced hemolytic 
activity (compared to nonporous silica particles) which correlates to their lower 
external surface area as a result of their porous structures 
37
. Similarly, lower hemolysis 
and cytotoxicity were generally observed for porous silica particles in Paper I, Paper III 
as well as a study by Rabolli et al. 
121
 in different cell types. However, more studies 
need to be performed to confirm this relationship.  
 
Gao et al. demonstrated pore-size dependent drug release rate and therefore anticancer 
activity using mesoporous silica nanoparticles in drug sensitive and drug resistant 
MCF-7 cell lines 
151
. Na et al. showed pore-size dependent delivery of siRNA in vitro 
and in vivo using mesoporous silica nanoparticles, particles with larger pores (23 nm) 
being more efficient than those with smaller pores (2 nm) 
152
. In Paper III, nonporous 
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silica nanoparticles were shown to have superior delivery efficiency compared to 
mesoporous silica nanoparticles with pore diameters of 2.4 nm. Several reasons could 
account for this observation: these mesoporous silica nanoparticles with 2.4 nm pore 
diameter have small pore spaces that could not be efficiently explored for the 
accommodation of cargo; the different distribution of functional groups over the 
surface of mesoporous and nonporous silica particles may subsequently affect their 
binding to nucleic acids as well as aggregation state; there might be less cellular 
association of mesoporous compared to nonporous silica nanoparticles as shown in a 
quantitative study using ICP-MS 
153
. Therefore, the dimensions of the pores could have 
a strong impact on the delivery efficiency of porous particles. 
 
The effect of plasma/serum. 
 
The effect of plasma/serum on nanoparticle behavior as well as their interactions with 
biological systems (particularly cytotoxicity and gene delivery efficiency) was 
examined in Papers I-III.  
 
In Paper I, the presence of a biological corona over silica particles was confirmed by 
means of X-ray photon electron spectroscopy (XPS). In Paper I, it was demonstrated 
that the plasma/serum corona is primarily composed of proteins, but lipids may also be 
involved. The zeta-potential of plasma corona coated particles tends to be fairly similar 
(-20±5 mV) despite the very different zeta-potential of pristine particles (-10 to -50 
mV). Monopoli et al. showed that the zeta-potential of 50 and 200 nm silica particles 
was modified by plasma corona (approx. from -25 to -10 mV), but the zeta-potential 
did not vary further with increasing concentrations of plasma (from 3% to 80%) 
56
. In 
Paper II, it was shown that the serum corona reduced the aggregation of nanoparticles 
(SiO2, TiO2, CeO2, ZnO) and in some cases (e.g. ZnO) enhanced their dissolution. 
Gualtieri et al. showed that 0.1% bovine serum albumin (BSA) reduced aggregation of 
silica nanoparticles 
154
 whereas studies by Monopoli et al. and Drescher et al. observed 
higher aggregation of silica and polystyrene nanoparticles in the presence of 
plasma/serum 
56, 155
. It was also shown that interactions of polymer-nucleic acid 
complexes with plasma proteins such as albumin leads to aggregation 
156, 157
.  
 
Interestingly, the coating of a pathogen with serum components is a mark for ingestion 
and destruction, a process termed opsonization, often resulting in phagocytosis and 
clearance from the circulation 
158
. Similarly, plasma/serum protein coating over 
polymer nanoparticles accelerated their removal by phagocytic cells 
157, 159
. Moreover, 
reduced cytotoxicity has been observed for nanoparticles in the presence of albumin 
160
. 
It is however questionable whether the reduced toxicity is due to the antioxidant 
activities of albumin or the coating of albumin over the reactive surface of these 
nanoparticles. Indeed, it was shown in Paper I-III that the presence of plasma/serum 
abolished or delayed the toxicity of pristine silica nanoparticles, amino-functionalized 
silica nanoparticles and ZnO nanoparticles. In Paper I, further evidence was presented 
that the plasma corona coating of the silica surface protected silica nanoparticles 
against hemolysis and cytotoxicity. The human plasma/serum may thus serve the 
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function to mediate the in vivo distribution and excretion of nanoparticles and reduce 
their toxic effects in the systemic circulation.  
 
On the other hand, reduced blood circulation time following the in vivo interactions of 
nanoparticle formulations with plasma proteins also impairs their delivery efficiency 
157
. Moreover, blood plasma/serum is also abundant in nucleic acid-degrading enzymes 
that can lead to a substantial loss of therapeutic effect 
161
. Therefore, research efforts are 
made towards using hydrophilic polymers (e.g. PEG) to shield nanoparticles from 
intensive interactions with blood proteins as well as searching for serum resistant 
formulations for delivery. For example, Lehto et al. showed that the delivery efficiency 
of a stearylated cell-penetrating peptide transportan 10 was maintained in the presence 
of serum proteins mimicking in vivo conditions 
162
. Silica particles provide promising 
serum resistant features for in vivo applications 
152
, although some discrepancy exists in 
our study and the literature. In Paper III, amino-functionalized silica particles displayed 
higher delivery efficiency for pDNA in MCF-7 cells in the presence of 10% serum than 
in the absence of serum, whereas Na et al. observed marginally lower delivery 
efficiency for siRNA in human cervical carcinoma HeLa cells with 10% serum than 
without serum 
152
. Nevertheless, Xiao et al. confirmed the protection of DNA by 
mesoporous silica particles from serum nucleases 
163
.    
 
In vitro vs. in vivo.  
 
Although numerous studies have used cell models to investigate the biocompatibility of 
nanomaterials and their applications for gene delivery, it is questionable how much 
knowledge from in vitro studies can be readily transferred to in vivo situations 
164
. First, 
in vitro systems lack the complexities of in vivo pharmacokinetics, physiological 
structures, and systemic responses. Second, particles, unlike small molecules, do not 
necessarily evenly distribute in fluids. On the contrary, they may exhibit distinct 
behaviors in body fluids and cell cultures 
142
. Third, cellular phenotypes (such as their 
repertoire of expressed receptors) may show significant variations in in vitro cell 
cultures 
165
. Nevertheless, in vitro studies may still prove to be useful in nanomedical 
research for identifying similar patterns of biologic activity and understanding the 
mechanisms of action 
166
. 
 
In addition to the in vivo approach for the administration of therapeutic nucleic acid 
formulations, the ex vivo approach first delivers the genetic material into cells grown in 
vitro (usually autologous cells from the same patient) and then introduce those 
transfected cells into the patient 
167
. 
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5.5 CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
Nanotechnologies hold great promises for numerous biomedical and diagnosis 
applications. Although nanomaterials have the potential to revolutionize the field of 
pharmaceutics and nucleic acid delivery 
168
, intensive research efforts are needed to 
develop safe, targeted, efficient delivery vectors. Importantly, studies to improve the 
understanding of their biocompatibility/toxicity and mechanisms of delivery are crucial 
to assist the rationale design of nanomaterials for delivery applications.  
 
In order to ensure the safety of using synthetic nanomaterials for delivery applications, 
thorough toxicology assessments linked to their physicochemical properties would be 
required. One of the primary concerns for future investigations is whether they cause 
cardiovascular adverse effects. It is noteworthy that small molecular drugs tend to 
cause more cardiovascular toxicity than hepatoxicity, especially in the long term 
169
. 
Interestingly, epidemiology studies of air pollution found fine particles (0.1-2.5 µm) 
associated with respiratory diseases and ultrafine particles (0.01-0.1 µm) associated 
with respiratory-cardiovascular diseases 
170
. It was suggested that nano-sized particles 
induce human vascular endothelial cell cytotoxic injury, inflammatory responses, and 
inhibition of cell growth, potentially causing cardiovascular diseases 
170, 171
. Radomski 
et al. reported nanoparticle-induced human platelet aggregation in vitro and rat vascular 
thrombosis in vivo 
172
, leading to possible systemic and cardiovascular risks. Moreover, 
it is important to identify which characteristic physicochemical properties may 
potentially cause cardiovascular toxicity. For example, surface charge is an important 
factor for the activation of the complement system and coagulation pathways 
173
.  
 
In the future, investigations directed towards the engineering of synthetic nanomaterials 
for gene delivery applications would be of considerable interests. For example, 
nanoparticles could be functionalized with PEG to better escape immune recognition 
and/or functionalized with targeting ligands for the active recognition of specific cells 
(e.g. targeting of folate receptors on tumor cells 
174
). Nanoparticles could be combined 
with cell penetrating peptides for enhanced delivery efficiency. Moreover, it would be 
of interests to investigate the mechanisms of delivery. Energy depletion and 
pharmacology inhibitors can be used to probe the mechanisms of cellular uptake, 
whereas in vitro liposome leakage assay can be used to mimic the process of 
endosomal escape. Last but not least, restoring or silencing of functional genes (e.g. 
tumor suppressor genes or oncogenes, respectively), as well as combined drug and gene 
delivery (e.g. to overcome drug resistance), can be investigated for specific therapeutic 
purposes. 
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